7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-12-31 
      
    		                                                                                    
      revenue:
    		                                                                                    
      product revenue
    		1,846,900,000 1,878,700,000 1,726,500,000                                                                                  
      revenue from anti-cd20 therapeutic programs
    		493,900,000 467,300,000 378,200,000 465,200,000 446,200,000 444,500,000 394,000,000 435,800,000 420,900,000 433,400,000 399,500,000 447,900,000 416,900,000 436,300,000 399,400,000 414,100,000 415,400,000 440,000,000 389,000,000                                                                  
      alzheimer's collaboration revenue
    		42,700,000 54,900,000 33,000,000                                                                                  
      contract manufacturing, royalty and other revenue
    		151,200,000 244,600,000 293,300,000 97,000,000 250,200,000 120,800,000 184,600,000 118,100,000 304,200,000 197,500,000 319,100,000                                                                          
      total revenue
    		2,534,700,000 2,645,500,000 2,431,000,000 2,454,700,000 2,465,800,000 2,464,900,000 2,290,500,000 2,386,300,000 2,530,300,000 2,456,000,000 2,463,000,000 2,544,000,000 2,508,500,000 2,589,100,000 2,531,800,000 2,733,800,000 2,778,900,000 2,775,000,000 2,694,000,000 2,852,600,000 3,376,100,000 3,681,600,000 3,534,300,000 3,671,300,000 3,600,100,000 3,616,700,000 3,489,800,000 3,526,300,000 3,439,000,000 3,356,500,000 3,131,100,000 3,307,000,000 3,077,800,000 3,078,400,000 2,810,700,000 2,872,000,000 2,955,800,000 2,894,200,000 2,726,800,000 2,839,336,000 2,777,859,000 2,591,642,000 2,554,963,000 2,640,675,000 2,511,446,000 2,421,452,000 2,129,751,000 1,965,850,000 1,827,780,000 1,723,473,000 1,415,096,000 1,417,941,000 1,385,554,000 1,420,951,000 1,292,014,000 3,738,700,000 1,309,934,000 1,208,647,000 1,203,342,000  1,175,800,000 1,212,702,000 1,108,860,000 3,256,830,000 1,120,518,000 1,093,289,000 1,036,484,000 1,068,913,000 1,092,964,000 993,444,000 942,186,000 893,300,000 789,231,000 773,176,000 715,910,000 708,341,000 703,492,000 660,041,000 611,175,000 632,853,000 596,211,000 605,634,000 587,802,000  
      yoy
    		2.79% 7.33% 6.13% 2.87% -2.55% 0.36% -7.00% -6.20% 0.87% -5.14% -2.72% -6.94% -9.73% -6.70% -6.02% -4.16% -17.69% -24.63% -23.78% -22.30% -6.22% 1.79% 1.28% 4.11% 4.68% 7.75% 11.46% 6.63% 11.74% 9.03% 11.40% 15.15% 4.13% 6.36% 3.08% 1.15% 6.41% 11.67% 6.73% 7.52% 10.61% 7.03% 19.97% 34.33% 37.40% 40.50% 50.50% 38.64% 31.92% 21.29% 9.53% -62.07% 5.77% 17.57% 7.37%  11.41% -0.33% 8.52%  4.93% 10.92% 6.98% 204.69% 2.52% 10.05% 10.01% 19.66% 38.48% 28.49% 31.61% 26.11% 12.19% 17.14% 17.14% 11.93% 17.99% 8.98% 3.98%      
      qoq
    		-4.19% 8.82% -0.97% -0.45% 0.04% 7.61% -4.01% -5.69% 3.03% -0.28% -3.18% 1.42% -3.11% 2.26% -7.39% -1.62% 0.14% 3.01% -5.56% -15.51% -8.30% 4.17% -3.73% 1.98% -0.46% 3.64% -1.04% 2.54% 2.46% 7.20% -5.32% 7.45% -0.02% 9.52% -2.13% -2.84% 2.13% 6.14% -3.96% 2.21% 7.19% 1.44% -3.25% 5.15% 3.72% 13.70% 8.34% 7.55% 6.05% 21.79% -0.20% 2.34% -2.49% 9.98% -65.44% 185.41% 8.38% 0.44%   -3.04% 9.36% -65.95% 190.65% 2.49% 5.48% -3.03% -2.20% 10.02% 5.44% 5.47% 13.19% 2.08% 8.00% 1.07% 0.69% 6.58% 8.00% -3.43% 6.15% -1.56% 3.03%   
      cost and expense:
    		                                                                                    
      cost of sales, excluding amortization and impairment of acquired intangible assets
    		674,400,000 605,000,000 629,300,000 583,500,000 638,700,000 546,000,000 542,200,000 618,300,000 659,600,000 592,700,000 662,800,000 570,900,000 469,500,000 484,000,000 753,900,000 660,100,000 511,800,000 459,700,000 478,100,000 490,600,000 449,100,000 411,100,000 454,300,000 447,100,000 430,000,000 476,300,000 602,000,000                                                          
      research and development
    		436,100,000 399,000,000 434,100,000 532,300,000 542,700,000 513,900,000 452,900,000 570,900,000 736,300,000 584,200,000 570,600,000 601,600,000 549,200,000 528,600,000 551,700,000 699,500,000 702,400,000 585,100,000 514,200,000 1,726,100,000 1,140,900,000 647,600,000 476,300,000 691,700,000 540,400,000 484,800,000 563,700,000 611,600,000 507,900,000 981,000,000 496,700,000 587,600,000 446,400,000 796,200,000 423,400,000 533,900,000 529,000,000 473,100,000 437,300,000 541,660,000 519,863,000 490,728,000 460,549,000 500,091,000 417,174,000 447,273,000 528,884,000 422,233,000 410,017,000 327,463,000 284,340,000 345,181,000 304,217,000 329,559,000 355,962,000 918,211,000 301,391,000 285,644,000 293,633,000   331,675,000 307,030,000 979,013,000 304,055,000 416,453,000 279,478,000 292,767,000 268,800,000 252,259,000 258,232,000 229,292,000 286,274,000 218,149,000 191,449,000 199,480,000 211,033,000 161,985,000 145,892,000 168,314,000 227,039,000 179,843,000 178,784,000  
      acquired in-process research and development, upfront and milestone expense
    		2,100,000 46,600,000 200,700,000                                                                                  
      selling, general and administrative
    		594,800,000 583,800,000 572,500,000 680,000,000 588,400,000 553,800,000 581,500,000 608,500,000 788,200,000 548,000,000 605,000,000 632,800,000 563,300,000 572,600,000 634,900,000 787,900,000 654,100,000 637,300,000 595,000,000 806,200,000 573,100,000 555,100,000 570,100,000 664,900,000 554,500,000 587,600,000 567,700,000 591,100,000 497,700,000 516,200,000 501,300,000 572,400,000 433,800,000 430,200,000 499,100,000 495,500,000 462,700,000 492,400,000 497,300,000 583,017,000 477,827,000 491,895,000 560,361,000 573,610,000 570,436,000 576,622,000 511,674,000 522,857,000 405,584,000 431,012,000 352,598,000 375,977,000 299,631,000 301,767,000 300,089,000 794,735,000 261,398,000 266,301,000 244,516,000   262,322,000 248,664,000 684,279,000 226,755,000 220,829,000 221,830,000 230,963,000 232,824,000 245,689,000 215,829,000 193,730,000 190,644,000 203,668,000 188,061,000 192,234,000 168,153,000 170,289,000 154,391,000 169,121,000 161,410,000 155,754,000 158,458,000  
      amortization and impairment of acquired intangible assets
    		135,700,000 130,900,000 111,800,000 151,200,000 130,300,000 86,900,000 78,300,000 76,600,000 60,900,000 52,900,000 50,200,000 175,000,000 56,500,000 67,500,000 66,900,000 68,100,000 111,000,000 604,100,000 98,100,000 249,200,000 82,600,000 61,500,000 71,500,000 67,700,000 283,900,000 70,100,000 68,200,000                                                          
      collaboration profit sharing/
    		87,200,000 75,000,000 58,100,000 57,100,000 69,300,000 62,400,000 65,600,000 54,300,000 50,500,000 56,900,000 57,100,000                                                                          
      (gain) loss on fair value remeasurement of contingent consideration
    		5,600,000 13,200,000 9,600,000 3,900,000 23,800,000       -195,400,000 -2,100,000 -4,500,000 -7,100,000 -1,600,000 -15,600,000 300,000 -33,800,000 -62,800,000 -29,000,000 10,000,000 -4,600,000 2,600,000 -57,800,000 -20,000,000  79,300,000 -87,900,000  -5,600,000 15,300,000 30,000,000 21,200,000 10,000,000 4,700,000 5,900,000 10,600,000 2,300,000 24,613,000 244,000 -2,201,000 7,844,000 7,320,000 -49,433,000 4,019,000 -799,000 2,436,000 -97,000 -5,163,000                                   
      restructuring charges
    		7,400,000 -700,000 35,300,000 5,300,000 6,800,000 6,600,000 11,500,000 98,800,000 76,000,000 34,400,000 9,600,000 7,000,000 15,400,000 70,600,000 38,100,000          300,000 800,000 400,000 2,800,000 6,000,000 1,600,000 1,600,000     11,800,000 11,600,000  9,700,000                                              
      gain on sale of priority review voucher
    		     -88,600,000                                                                               
      other income
    		34,100,000 48,700,000 68,400,000 149,900,000 14,800,000 85,200,000 93,700,000 67,300,000 300,000,000 -121,200,000 69,400,000 113,100,000 -56,000,000 -428,600,000 -263,300,000 -182,100,000 -502,900,000 96,400,000 -506,900,000 683,500,000 -128,600,000 63,000,000 -120,500,000 -49,300,000 -27,300,000 -197,400,000 357,300,000 -28,600,000 115,100,000 -34,500,000 -41,000,000 -66,000,000 -43,600,000 -68,200,000 -37,600,000 -48,000,000 -58,100,000 -58,500,000 -52,800,000 -82,412,000 -15,413,000 -10,889,000 -14,986,000 -8,751,000 -16,290,000 4,861,000 -5,601,000 -5,405,000 -4,640,000 -10,428,000 -14,457,000 -14,290,000 -4,548,000 2,950,000 15,144,000 -5,750,000 -7,727,000 -11,728,000 9,951,000   1,012,000 -8,386,000 27,892,000 9,360,000 14,680,000 6,846,000 -34,850,000 -24,725,000 -5,463,000 370,000 32,631,000 44,904,000 31,586,000 21,702,000 -10,647,000 22,319,000 21,806,000 18,665,000 11,837,000 11,192,000 6,051,000 -8,926,000  
      total cost and expense
    		1,977,400,000 1,901,500,000 2,119,800,000 2,163,200,000 2,014,800,000 1,766,200,000 1,825,700,000 2,094,700,000 2,671,500,000 1,747,900,000 2,024,700,000 1,940,200,000 1,137,400,000 1,319,600,000 1,921,100,000 2,146,700,000 1,984,900,000 2,289,300,000 1,720,100,000                                                                  
      income before income tax (benefit) expense
    		557,300,000 744,000,000 311,200,000 403,625,000 451,000,000 698,700,000 464,800,000                                                                              
      income tax (benefit) expense
    		90,800,000 109,200,000 70,700,000 24,800,000 62,500,000 115,100,000 71,400,000 42,700,000 -72,900,000 114,800,000 50,700,000 54,300,000 236,200,000 216,700,000 125,600,000 443,200,000 -25,900,000 -409,100,000                                                                   
      net income attributable to biogen inc.
    		466,500,000 634,800,000 240,500,000 266,700,000 388,500,000 583,600,000 393,400,000 249,700,000 -68,100,000 591,600,000 387,900,000 550,400,000 1,134,700,000 1,058,000,000 303,800,000 368,200,000 329,200,000 448,500,000 410,200,000 357,900,000 701,500,000 1,542,100,000 1,399,100,000 1,439,700,000 1,545,900,000 1,494,100,000 1,408,800,000 946,800,000 1,444,400,000 866,600,000 1,172,900,000 -297,400,000 1,226,100,000 862,800,000 747,600,000 649,200,000 1,032,900,000 1,049,800,000 970,900,000 831,561,000 965,622,000 927,276,000 822,541,000                                          
      net income per share
    		                                                                                    
      basic earnings per share attributable to biogen inc.
    		3.18 4.33 1.65 1.83 2.67 4.01 2.71 1.72 -0.47 4.09 2.69 3.84 7.86 7.25 2.06 2.51 2.22 3 2.7 2.57 4.47 9.6 8.1 8.09 8.4 7.85 7.17 4.77 7.17 4.18 5.55 -1.38 5.8 4.07 3.47 3.01 4.72 4.79 4.44 3.78 4.16 3.94 3.5                                          
      diluted earnings per share attributable to biogen inc.
    		3.17 4.33 1.64 1.83 2.66 4 2.7 1.71 -0.47 4.07 2.67 3.8 7.84 7.24 2.06 2.5 2.22 2.99 2.69 2.55 4.46 9.59 8.08 8.07 8.39 7.85 7.15 4.75 7.15 4.18 5.54 -1.38 5.79 4.07 3.46 3.01 4.71 4.79 4.43 3.77 4.15 3.93 3.49                                          
      weighted-average shares used for eps calculation
    		                                                           254.9                         
      product
    		   1,345,225,000 1,769,400,000 1,899,600,000 1,711,900,000 1,353,575,000 1,805,200,000 1,845,800,000 1,763,300,000 1,904,500,000 1,962,100,000 2,054,900,000 2,066,300,000 2,193,500,000 2,205,700,000 2,236,000,000 2,211,700,000 2,301,600,000 2,690,300,000 2,795,700,000 2,904,600,000 2,924,800,000 2,894,700,000 2,880,300,000 2,680,000,000 2,825,700,000 2,780,100,000 2,757,500,000 2,523,500,000 2,712,400,000 2,622,500,000 2,639,700,000 2,380,100,000 2,502,900,000 2,539,600,000 2,466,000,000 2,309,400,000 2,425,895,000 2,391,717,000 2,198,566,000 2,172,322,000 2,286,981,000 2,117,366,000 2,056,292,000 1,742,765,000 1,607,080,000 1,453,554,000 1,385,918,000 1,095,779,000 1,074,676,000 1,039,110,000 1,076,800,000 975,488,000 2,860,360,000 975,757,000 956,703,000 907,102,000   859,235,000 824,220,000 2,351,252,000 801,689,000 790,970,000 733,409,000 731,835,000 758,260,000 684,486,000 665,070,000 604,227,000 529,581,000 518,625,000 484,388,000 463,617,000 475,096,000 436,081,000 406,519,000 429,231,000 391,366,000 398,822,000 397,584,000  
      net income
    		   266,700,000 388,500,000 583,600,000 393,400,000 248,900,000 -68,300,000 593,300,000 387,600,000 549,500,000 1,134,900,000 1,058,700,000 218,500,000 -20,500,000 318,100,000 1,025,500,000 404,600,000 357,600,000 703,900,000 1,606,500,000 1,392,600,000 1,439,700,000 1,545,900,000 1,494,100,000 1,408,800,000 944,900,000 1,442,900,000 915,000,000 1,171,200,000 -166,300,000 1,226,100,000 862,800,000 747,500,000 647,900,000 1,030,200,000 1,048,400,000 969,200,000 828,708,000 1,019,493,000 924,825,000 820,174,000 882,585,000 856,120,000 723,132,000 479,728,000 457,306,000 487,616,000 490,670,000 426,749,000 292,127,000 398,400,000 387,141,000 302,366,000 913,024,000 353,662,000 304,049,000 308,766,000   294,649,000 219,993,000 697,460,000 279,602,000 144,885,000 246,579,000 206,654,000 206,788,000 206,628,000 163,097,000 201,150,000 119,381,000 186,140,000 131,501,000 108,556,000 156,599,000 -170,613,000 122,969,000 55,562,000 27,185,000 34,504,000 43,458,000  
      yoy
    		   7.15% -668.81% -1.63% 1.50% -54.70% -106.02% -43.96% 77.39% -2780.49% 256.77% 3.24% -46.00% -105.73% -54.81% -36.17% -70.95% -75.16% -54.47% 7.52% -1.15% 52.37% 7.14% 63.29% 20.29% -668.19% 17.68% 6.05% 56.68% -125.67% 19.02% -17.70% -22.87% -21.82% 1.05% 13.36% 18.17% -6.10% 19.08% 27.89% 70.97% 93.00% 75.57% 47.38% 12.41% 56.54% 22.39% 26.74% 41.14% -68.00% 12.65% 27.33% -2.07%   3.19% 40.35%   103.37% -10.78% 237.50% 35.21% -29.88% 51.19% 2.74% 73.22% 11.01% 24.03% 85.30% -23.77% -209.10% 6.94% 95.38% 476.05% -594.47% 182.96%      
      qoq
    		   -31.35% -33.43% 48.35% 58.06% -464.42% -111.51% 53.07% -29.46% -51.58% 7.20% 384.53% -1165.85% -106.44% -68.98% 153.46% 13.14% -49.20% -56.18% 15.36% -3.27% -6.87% 3.47% 6.05% 49.10% -34.51% 57.69% -21.88% -804.27% -113.56% 42.11% 15.42% 15.37% -37.11% -1.74% 8.17% 16.95% -18.71% 10.24% 12.76% -7.07% 3.09% 18.39% 50.74% 4.90% -6.22% -0.62% 14.98% 46.08% -26.67% 2.91% 28.04% -66.88% 158.16% 16.32% -1.53%    33.94% -68.46% 149.45% 92.98% -41.24% 19.32% -0.06% 0.08% 26.69% -18.92% 68.49% -35.86% 41.55% 21.14% -30.68% -191.79% -238.74% 121.32% 104.38% -21.21% -20.60%   
      net income margin %
    		0% 0% 0% 10.86% 15.76% 23.68% 17.18% 10.43% -2.70% 24.16% 15.74% 21.60% 45.24% 40.89% 8.63% -0.75% 11.45% 36.95% 15.02% 12.54% 20.85% 43.64% 39.40% 39.21% 42.94% 41.31% 40.37% 26.80% 41.96% 27.26% 37.41% -5.03% 39.84% 28.03% 26.59% 22.56% 34.85% 36.22% 35.54% 29.19% 36.70% 35.68% 32.10% 33.42% 34.09% 29.86% 22.53% 23.26% 26.68% 28.47% 30.16% 20.60% 28.75% 27.25% 23.40% 24.42% 27.00% 25.16% 25.66%  0% 24.30% 19.84% 21.42% 24.95% 13.25% 23.79% 19.33% 18.92% 20.80% 17.31% 22.52% 15.13% 24.07% 18.37% 15.33% 22.26% -25.85% 20.12% 8.78% 4.56% 5.70% 7.39%  
      net income attributable to noncontrolling interests, net of tax
    		       -800,000 -200,000 1,700,000 -300,000 -900,000 200,000 700,000 -85,300,000 -388,700,000 -11,100,000 577,000,000 -5,600,000 -300,000 2,400,000 64,400,000 -6,500,000     -1,900,000 -1,500,000 48,400,000 -1,700,000 131,100,000   -100,000 -1,300,000 -2,700,000 -1,400,000 -1,700,000 -2,853,000 53,871,000 -2,451,000 -2,367,000 -879,000 -738,000 8,626,000 -228,000       295,000 -295,000 30,422,000 1,836,000 16,015,000 14,435,000                          
      gain on sale of building
    		            -503,700,000                                                                        
      income before income tax (benefit) expense and equity in loss of investee, net of tax
    		       291,600,000 -141,200,000                                                                            
      equity in (income) loss of investee, net of tax
    		             -5,900,000 3,300,000 -17,700,000 -1,100,000 -34,300,000 18,200,000 -18,000,000 13,100,000 -15,100,000                                                               
      revenue from leqembi collaboration
    		         -20,700,000 -18,900,000                                                                          
      income before income tax expense and equity in loss of investee, net of tax
    		         708,100,000 438,300,000 603,800,000 1,371,100,000 1,269,500,000 347,400,000 405,000,000 291,100,000 582,100,000 467,000,000 352,900,000 957,800,000 2,037,500,000 1,699,400,000 1,728,400,000 1,779,000,000 1,758,500,000 1,860,000,000 1,414,500,000 1,812,700,000 1,178,700,000 1,493,700,000 1,399,800,000 1,609,900,000 1,132,400,000 986,700,000 838,200,000 1,367,200,000 1,402,000,000 1,325,600,000 1,085,785,000 1,356,419,000 1,222,207,000 1,102,889,000 1,151,012,000 1,136,288,000 993,586,000 665,747,000 652,521,000 679,891,000 652,099,000 496,068,000 431,217,000 530,702,000 508,673,000                               
      other
    		           191,600,000 129,500,000 97,900,000 66,100,000 126,200,000 157,800,000 99,000,000 93,300,000 132,000,000 125,700,000 407,600,000 109,300,000 145,700,000 109,600,000 160,000,000 292,400,000 165,700,000 147,200,000 108,600,000 164,400,000 179,600,000 48,800,000 41,600,000 90,000,000 50,900,000 98,600,000 79,000,000 87,900,000 79,543,000 48,961,000 55,566,000 52,030,000 49,164,000 103,402,000 61,864,000 90,101,000 89,354,000 71,016,000 48,770,000 54,711,000 62,317,000 58,652,000 59,521,000 31,974,000 148,214,000 67,706,000 35,486,000 40,116,000   47,096,000 29,712,000        29,893,000 18,333,000 25,013,000 23,961,000 24,358,000          
      collaboration profit sharing
    		           35,200,000 45,300,000 29,400,000 -117,300,000 -67,300,000 21,200,000 -15,200,000 68,500,000 66,400,000 73,000,000 21,800,000 71,800,000 59,800,000 60,200,000 63,500,000 58,100,000 55,800,000 47,500,000 39,200,000 42,500,000 29,800,000 35,200,000 26,500,000 20,800,000 11,100,000 4,700,000 -5,600,000             85,357,000 77,944,000 75,545,000 78,511,000 85,894,000 236,296,000 81,475,000 88,050,000 74,794,000   62,692,000 63,557,000 155,207,000 60,697,000 49,138,000 42,773,000 37,673,000 43,533,000 33,429,000 21,406,000 13,909,000 5,842,000 -105,000 -5,567,000          
      acquired in-process research and development
    		                 18,000,000     75,000,000      27,500,000 75,000,000 10,000,000   120,000,000                             39,976,000         35,808,000 29,959,000  18,405,000   330,520,000       
      income from operations
    		              610,700,000 587,100,000 794,000,000 485,700,000 973,900,000 -330,600,000 1,086,400,000 1,974,500,000 1,819,900,000 1,777,700,000 1,806,300,000 1,955,900,000 1,502,700,000 1,443,100,000 1,697,600,000 1,213,200,000 1,534,700,000 1,465,800,000 1,653,500,000 1,200,600,000 1,024,300,000 886,200,000 1,425,300,000 1,460,500,000 1,378,400,000 1,168,197,000 1,371,832,000 1,233,096,000 1,117,875,000 1,159,763,000 1,152,578,000 988,725,000 671,348,000 657,926,000 684,531,000 662,527,000 510,525,000 445,507,000 535,250,000 505,723,000 369,370,000 1,236,198,000 488,493,000 410,813,000 416,283,000  194,100,000 395,880,000 303,689,000 911,249,000 384,178,000 222,914,000 304,958,000 324,960,000 345,850,000 296,797,000 246,004,000 262,430,000 129,210,000 206,440,000 181,692,000 191,718,000 197,328,000 -122,015,000 172,989,000 93,299,000 21,165,000 46,301,000 75,274,000  
      yoy
    		              -37.29% -277.59% -26.91% -75.40% -46.49% -118.60% -39.85% 0.95% 21.11% 23.19% 6.40% 61.22% -2.09% -1.55% 2.67% 1.05% 49.83% 65.40% 16.01% -17.80% -25.69% -24.14% 3.90% 18.44% 23.31% 0.73% 19.02% 24.72% 66.51% 76.28% 68.37% 49.24% 31.50% 47.68% 27.89% 31.01% 38.22% -63.96% 9.57% 23.10% -11.27%  151.67% 3.77% 37.08%  -49.48% 77.59% -0.42% 180.42% 11.08% -24.89% 23.96% 23.83% 167.67% 43.77% 35.40% 36.88% -34.52% -269.19% 5.03% 105.49% 832.33% -363.53% 129.81%      
      qoq
    		              4.02% -26.06% 63.48% -50.13% -394.59% -130.43% -44.98% 8.49% 2.37% -1.58% -7.65% 30.16% 4.13% -14.99% 39.93% -20.95% 4.70% -11.35% 37.72% 17.21% 15.58% -37.82% -2.41% 5.96% 17.99% -14.84% 11.25% 10.31% -3.61% 0.62% 16.57% 47.27% 2.04% -3.89% 3.32% 29.77% 14.59% -16.77% 5.84% 36.92% -70.12% 153.06% 18.91% -1.31%   -50.97% 30.36% -66.67% 137.19% 72.34% -26.90% -6.16% -6.04% 16.53% 20.65% -6.26% 103.10% -37.41% 13.62% -5.23% -2.84% -261.72% -170.53% 85.41% 340.82% -54.29% -38.49%   
      operating margin %
    		0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 24.12% 21.48% 28.57% 17.50% 36.15% -11.59% 32.18% 53.63% 51.49% 48.42% 50.17% 54.08% 43.06% 40.92% 49.36% 36.14% 49.01% 44.32% 53.72% 39.00% 36.44% 30.86% 48.22% 50.46% 50.55% 41.14% 49.38% 47.58% 43.75% 43.92% 45.89% 40.83% 31.52% 33.47% 37.45% 38.44% 36.08% 31.42% 38.63% 35.59% 28.59% 33.06% 37.29% 33.99% 34.59%  16.51% 32.64% 27.39% 27.98% 34.29% 20.39% 29.42% 30.40% 31.64% 29.88% 26.11% 29.38% 16.37% 26.70% 25.38% 27.07% 28.05% -18.49% 28.30% 14.74% 3.55% 7.65% 12.81%  
      income tax expense
    		                  44,200,000 13,300,000 240,800,000 446,100,000 292,000,000 276,100,000 211,300,000 248,100,000 422,500,000 469,600,000 369,800,000 263,700,000 322,500,000 1,566,100,000 383,800,000 269,600,000 239,200,000 190,300,000 337,000,000 353,600,000 356,400,000 257,125,000 330,093,000 292,501,000 281,881,000 268,233,000 274,774,000 268,521,000 178,414,000 190,261,000 186,105,000 159,140,000 65,508,000 136,341,000 131,044,000 121,021,000 82,148,000 317,424,000 127,104,000 95,036,000 117,468,000   102,243,000 75,310,000 241,681,000 113,936,000 92,709,000 65,225,000 83,456,000 114,337,000 84,706,000 83,277,000 93,911,000 54,733,000 51,886,000 71,893,000 72,515,000 63,048,000 70,404,000       
      revenues:
    		                                                                                    
      revenues from anti-cd20 therapeutic programs
    		                   419,000,000 560,100,000 478,300,000 520,400,000 600,800,000 595,800,000 576,400,000 517,400,000 534,900,000 511,700,000 490,400,000 443,200,000 415,000,000 406,500,000 397,100,000 340,600,000 318,200,000 317,600,000 349,200,000 329,500,000                                              
      cost and expenses:
    		                                                                                    
      loss on divestiture of hillerød, denmark manufacturing operations
    		                       -40,200,000 -17,700,000                                                            
      total cost and expenses
    		                   3,183,200,000 2,289,700,000 1,707,100,000 1,714,400,000 1,893,600,000 1,793,800,000 1,660,800,000 1,987,100,000 2,083,200,000 1,741,400,000 2,143,300,000 1,596,400,000 1,841,200,000 1,424,300,000 1,877,800,000 1,786,400,000 1,985,800,000 1,530,500,000 1,433,700,000 1,348,400,000 1,671,139,000 1,406,027,000 1,358,546,000 1,437,088,000 1,485,532,000 1,363,247,000 1,436,627,000 1,462,262,000 1,315,503,000 1,150,198,000 1,066,265,000 909,622,000 987,507,000 882,023,000 915,228,000 922,644,000 2,502,502,000 821,441,000 797,834,000 787,059,000                          
      equity in loss of investee, net of tax
    		                      14,800,000 12,600,000 21,800,000 16,300,000 28,700,000             -48,000 6,833,000 4,881,000 834,000 194,000 5,394,000 1,933,000 7,605,000 4,954,000 6,170,000 2,289,000 3,811,000 2,749,000 1,258,000 511,000                               
      loss on assets and liabilities held for sale
    		                         -2,300,000 115,500,000                                                          
      gain on fair value remeasurement of contingent consideration
    		                          11,500,000   1,900,000                                                       
      cost of sales, excluding amortization of acquired intangible assets
    		                           331,950,000 460,800,000 421,000,000 446,000,000 509,200,000 370,000,000 366,200,000 384,600,000 378,500,000 416,900,000 370,300,000 313,000,000 331,821,000 310,028,000 286,120,000 312,431,000 297,265,000 302,639,000 291,887,000 279,245,000 258,553,000 234,696,000 230,728,000 133,749,000 133,828,000 139,358,000 139,112,000 133,197,000 343,253,000 123,527,000 100,503,000 103,113,000   106,985,000 97,055,000 288,618,000 93,486,000 90,721,000 98,197,000 101,161,000 107,493,000 92,401,000 100,934,000 87,566,000 81,613,000 84,063,000 81,950,000          
      amortization of acquired intangible assets
    		                           123,300,000 281,900,000 107,400,000 103,900,000 139,800,000 108,900,000 117,500,000 448,500,000 104,200,000 99,700,000 92,900,000 88,800,000 96,628,000 98,065,000 92,004,000 95,903,000 107,246,000 122,431,000 116,826,000 143,258,000 109,424,000 99,998,000 82,225,000 51,301,000 50,948,000 53,013,000 52,282,000 45,961,000 159,219,000 49,347,000 55,136,000 53,216,000   53,148,000 48,889,000 238,464,000 51,347,000 93,234,000 89,248,000 90,631,000 94,464,000 72,869,000 74,781,000 70,925,000 65,689,000 60,961,000 59,920,000 60,020,000 60,011,000 76,260,000 70,707,000 73,559,000 75,990,000 77,078,000 75,677,000  
      unconsolidated joint business
    		                                       333,898,000 337,181,000 337,510,000 330,611,000 304,530,000 290,678,000 303,296,000 296,885,000 269,416,000 303,210,000 288,785,000 264,606,000 280,948,000 287,792,000 284,630,000 284,552,000 730,126,000 266,471,000 216,458,000 256,124,000   306,371,000 254,928,000 810,944,000 283,919,000 275,570,000 278,818,000 303,214,000 298,979,000 278,822,000 247,223,000 253,707,000 234,637,000 230,590,000 207,164,000 217,568,000 203,820,000 206,095,000 183,380,000 131,746,000 181,597,000 184,934,000 160,453,000  
      gain on sale of rights
    		                                           4,620,000 4,379,000 3,900,000 3,859,000 7,579,000 6,949,000 5,319,000 5,051,000 15,073,000 31,719,000                                
      net income attributable to biogen idec inc.
    		                                           883,464,000 856,858,000 714,506,000 479,956,000 457,306,000 487,616,000 490,670,000 426,749,000 292,127,000 398,400,000 386,846,000 302,661,000 882,602,000 351,826,000 288,034,000 294,331,000   293,438,000 217,442,000 692,469,000 277,663,000 142,845,000 243,987,000                  
      basic earnings per share attributable to biogen idec inc.
    		                                           3.75 3.63 3.02 2.03 1.93 2.06 2.07 1.8 1.24 1.68 1.62 1.26 3.64 1.45 1.19 1.22   1.13 0.8 2.41 0.96 0.49 0.85                  
      diluted earnings per share attributable to biogen idec inc.
    		                                           3.73 3.62 3.01 2.02 1.92 2.05 2.06 1.79 1.23 1.67 1.61 1.25 3.61 1.43 1.18 1.2   1.12 0.8 2.4 0.95 0.49 0.84                  
      restructuring charge
    		                                                    803,000 1,139,000 283,000 17,223,000 1,803,000  16,587,000                          
      fair value adjustment of contingent consideration
    		                                                  2,277,000 3,629,000 9,456,000 12,858,000 1,258,000 33,565,000 2,500,000 2,200,000 1,200,000                          
      income before income tax expense
    		                                                      384,514,000 1,230,448,000 480,766,000 399,085,000 426,234,000   396,892,000 295,303,000 939,141,000 393,538,000 237,594,000 311,804,000 214,708,250 321,125,000 291,334,000 246,374,000              
      net income attributable to biogen idec
    		                                                            254,100,000                        
      diluted earnings per share attributable to biogen idec
    		                                                            1.05                        
      costs and expenses:
    		                                                                                    
      total costs and expenses
    		                                                             816,822,000 805,171,000 2,345,581,000 736,340,000 870,375,000 731,526,000 743,953,000 747,114,000 696,647,000 696,182,000 630,870,000 660,021,000 566,736,000 534,218,000 516,623,000 506,164,000 782,056,000 438,186,000 539,554,000 575,046,000 559,333,000 512,528,000  
      net income attributable to noncontrolling interest, net of tax
    		                                                             1,211,000 2,551,000 4,991,000 1,939,000 2,040,000 2,592,000                  
      other revenues
    		                                                               8,727,500 34,910,000 26,749,000 24,257,000 33,864,000 35,725,000 30,136,000               
      in-process research and development
    		                                                                   6,250,000   25,000,000              
      basic earnings per share
    		                                                                   0.7 0.71 0.71 0.55 0.67 0.41 0.55 0.39 0.32 0.46 -0.5 0.36 0.17 0.08 0.1 0.13  
      diluted earnings per share
    		                                                                   0.7 0.7 0.7 0.54 0.65 0.41 0.54 0.38 0.32 0.45 -0.5 0.36 0.16 0.08 0.1 0.12  
      facility impairments and gain on sale
    		                                                                           -230,750 175,000        
      gain on settlement of license agreement
    		                                                                           -8,548,000  -34,192,000       
      income before income tax provision and cumulative effect of accounting change
    		                                                                       295,061,000 174,114,000 238,026,000    -100,209,000 191,654,000      
      income before cumulative effect of accounting change
    		                                                                       201,150,000 119,381,000 186,140,000 131,501,000 108,556,000 156,599,000 -170,613,000 119,190,000      
      cumulative effect of accounting change, net of income tax
    		                                                                           -3,778,999.99   3,779,000      
      basic earnings per share:
    		                                                                                    
      diluted earnings per share:
    		                                                                                    
      gain on sale of long lived assets
    		                                                                                    
      shares used in calculating:
    		                                                                                    
      gain on sale of long-lived assets
    		                                                                                    
      income before income tax expense and cumulative effect of accounting change
    		                                                                          203,394,000 181,071,000 219,647,000        
      royalty
    		                                                                           15,178,500 21,867,000 18,286,000 20,561,000      
      corporate partner
    		                                                                           750,500 2,709,000 -421,000 715,000 132,000 131,000 144,000 3,016,000  
      cost of product revenues, excluding amortization of acquired intangible assets
    		                                                                           52,298,750 65,742,000 77,060,000 66,391,000      
      cost of royalty revenues
    		                                                                           771,250 1,050,000 933,000 1,103,000 1,237,000 1,203,000 849,000 1,128,000  
      facility impairments and loss on sale
    		                                                                             -799,000 -298,000 15,208,000 21,046,000    
      income tax provision
    		                                                                              72,464,000 11,477,500 5,172,000    
      royalties
    		                                                                               21,593,000 23,117,000 21,734,000 26,749,000  
      cost of product revenues
    		                                                                               64,270,750 88,358,000 70,244,000 98,481,000  
      income before income tax provision
    		                                                                               37,764,750 32,357,000 52,352,000 66,348,000  
      loss on sale of manufacturing facility
    		                                                                                 75,565,000   
      income tax benefit
    		                                                                                 17,848,000 22,890,000  
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.